2022 Year in Review - Cholangiocarcinoma

Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection.

Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.

A systematic review of phase 2 and 3 clinical trials for biliary tract cancers revealed quality-of-life assessments were not routinely included as trial outcomes.

The phase 2 STAMP study revealed negligible differences in disease-free survival and overall survival between adjuvant gemcitabine/cisplatin versus capecitabine in lymph node–positive extrahepatic cholangiocarcinoma but found increased grade 3/4 adverse events with gemcitabine/cisplatin.

Investigators found the addition of toripalimab to a gemcitabine-based chemotherapy regimen as first-line treatment of advanced biliary tract cancers demonstrated encouraging efficacy.

A single-institution study found that liver-directed radiation therapy was associated with favorable tumor-related liver failure and survival times in patients with metastatic intrahepatic or extrahepatic cholangiocarcinoma.

Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma.

Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy.

Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.

The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer.